Valproic acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts

Clinical Cancer Research

Volumn 12, Issue 15, 2006, Pages 4687-4694

  Shu, Qin ^a   Antalffy, Barbara ^a   Su, Jack Meng Feng ^a   Adesina, Adekunle ^a   Ou, Ching Nan ^a   Pietsch, Torsten ^b   Blaney, Susan M ^a   Lau, Ching C ^a   Li, Xiao Nan ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; MICROTUBULE ASSOCIATED PROTEIN 2; VALPROIC ACID; VIMENTIN;

ACETYLATION; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOGENICITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNE DEFICIENCY; IN VIVO STUDY; MEDULLOBLASTOMA; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; OSMOTIC MINIPUMP; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR GROWTH; TUMOR MODEL; TUMOR REGRESSION; XENOGRAFT;

ANIMALS; CARCINOGENICITY TESTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CEREBELLAR NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, SUBCUTANEOUS; MEDULLOBLASTOMA; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; STRUCTURE-ACTIVITY RELATIONSHIP; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS; VALPROIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33748053974     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2849     Document Type: Article

References (49)

1. Packer RJ, Rood BR, MacDonald TJ. Medulloblastoma: present concepts of stratification into risk groups. Pediatr Neurosurg 2003;39:60-7.
2. Rood BR, Mac Donald TJ, Packer RJ. Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol 2004;31:666-75.
3. Dyer MA. Mouse models of childhood cancer of the nervous system. J Clin Pathol 2004;57:561-76.
4. Kamb A. What's wrong with our cancer models? Nat Rev Drug Discov 2005;4:161-5.
5. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2003;2:S134-9.
6. Holland EC. Mouse models of human cancer as tools in drug development. Cancer Cell 2004;6:197-8.
7. Raffel C. Medulloblastoma: molecular genetics and animal models. Neoplasia 2004;6:310-22.
8. Green JE, Hudson T. The promise of genetically engineered mice for cancer prevention studies. Nat Rev Cancer 2005;5:184-98,
9. Goodrich LV, Milenkovic L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997;277:1109-13.
10. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996;272:1668-71.
11. Zurawel RH, Allen C, Wechsler-Reya R, Scott MP, Raffel C. Evidence that haploinsufficiency of Ptch leads to medulloblastoma in mice. Genes Chromosomes Cancer 2000;28:77-81.
12. Wetmore C, Eberhart DE, Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res 2001;61:513-6.
13. Hallahan AR, Pritchard JI, Hansen S, et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedge-hog induced medulloblastomas. Cancer Res 2004;64:7794-800.
14. Lee Y, McKinnon PJ. DNA Ligase IV suppresses medulloblastoma formation. Cancer Res 2002;62:6395-9.
15. Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999;17:343-59.
16. Lang JY, Chen H, Zhou J, et al. Antimetastatic effect of salvicine on human breast cancer MDA-MB-435 Orthotopic xenograft is closely related to Rho-dependent pathway. Clin Cancer Res 2005;11:3455-64.
17. Kim S, Park YW, Schiff BA, et al. An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clin Cancer Res 2005;11:1713-21.
18. Zhang X, Galardi E, Duquette M, Delic M, Lawler J, Parangi S. Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an Orthotopic human pancreatic cancer model. Clin Cancer Res 2005;11:2337-44.
19. Capella G, Farre L, Villanueva A, et al. Orthotopic models of human pancreatic cancer. Ann N Y Acad Sci 1999;880:103-9.
20. Yokoi K, Thaker PH, Yazici S, et al. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res 2005;65:3716-25.
21. Hoffman RM. Orthotopic transplant mouse models with green fluorescent protein-expressing cancer cells to visualize metastasis and angiogenesis. Cancer Metastasis Rev 1998;17:271-7.
22. Horiuchi H, Kawamata H, Fujimori T, Kuroda Y. A MEK inhibitor (U0126) prolongs survival in nude mice bearing human gallbladder cancer cells with K-ras mutation: analysis in a novel orthotopic inoculation model. Int J Oncol 2003;23:957-63.
23. Kim SJ, Johnson M, Koterba K, Herynk MH, Uehara H, Gallick GE. Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-4 prostate tumor cells in an orthotopic nude mouse model. Clin Cancer Res 2003;9:5161-70.
24. Lefranc F, James S, Camby I, et al. Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts. J Neurosurg 2005;102:706-14.
25. Giannini C, Sarkaria JN, Saito A, et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-oncol 2005;7:164-76.
26. Eyupoglu IY, Hahnen E, Buslei R, et al. Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J Neurochem 2005;93:992-9.
27. Burgos JS, Rosol M, Moats RA, et al. Time course of bioluminescent signal in orthotopic and heterotopic brain tumors in nude mice. Biotechniques 2003;34:1184-8.
28. Friedman HS, Schold SC, Jr., Varia M, Bigner DD. Chemotherapy and radiation therapy of human medulloblastoma in athymic nude mice. Cancer Res 1983;43:3088-93.
29. Friedman HS, Bigner SH, McComb RD, et al. A model for human medulloblastoma. Growth, morphology, and chromosomal analysis in vitro and in athymic mice. J Neuropathol Exp Neurol 1983;42:485-503.
30. Friedman HS, Schold SC, Jr., Bigner DD. Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice. Cancer Res 1986;46:224-8.
31. Slagel DE, Feola J, Houchens DP, Ovejera AA. Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model. Cancer Res 1982;42:812-6.
32. Vachon P, Girard C, Theoret Y. Effects of basic fibroblastic growth factor on the growth of human medulloblastoma xenografts. J Neurooncol 2004;67:139-46.
33. Nelson AL, Algon SA, Munasinghe J, et al. Magnetic resonance imaging of patched heterozygous and xenografted mouse brain tumors. J Neurooncol 2003;62:259-67.
34. Schabet M, Martos J, Buchholz R, Pietsch T. Animal model of human medulloblastoma: clinical, magnetic resonance imaging, and histopathological findings after intra-cisternal injection of MHH-MED-1 cells into nude rats. Med Pediatr Oncol 1997;29:92-7.
35. Yang WQ, Senger D, Muzik H, et al. Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. Cancer Res 2003;63:3162-72.
36. Blaheta RA, Cinatl J, Jr. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 2002;22:492-511.
37. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 2005;4:1912-22.
38. Waha A, Waha A, Koch A, et al. Epigenetic silencing of the HIC-1 gene in human medulloblastomas. J Neuropathol Exp Neurol 2003;62:1192-201.
39. Pietsch T, Scharmann T, Fonatsch C, et al. Characterization of five new cell lines derived from human primitive neuroectodermal tumors of the central nervous system. Cancer Res 1994;54:3278-87.
40. Li XN, Parikh S, Shu Q, et al. Phenylbutyrate and phenylacetate induce differentiation and inhibit proliferation of human medulloblastoma cells. Clin Cancer Res 2004;10:1150-9.
41. Liu Y, Saad RS, Shen SS, Silverman JF. Diagnostic value of microtubule-associated protein-2 (MAP-2) for neuroendocrine neoplasms. Adv Anat Pathol 2003;10:101-6.
42. Katsetos CD, Legido A, Perentes E, Mork SJ. Class III β-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology. J Child Neurol 2003;18:851-66.
43. Lampson LA. New animal models to probe brain tumor biology, therapy, and immunotherapy: advantages and remaining concerns. J Neurooncol 2001;53:275-87.
44. Lindsey JC, Lusher ME, Anderton JA, et al. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Carcinogenesis 2004;25:661-8.
45. Lee SH, Kang HS, Rhee CH, et al. Growth-inhibitory effect of adenovirus-mediated p53 gene transfer on medulloblastoma cell line, Daoy, harboring mutant p53. Childs Nerv Syst 2001;17:134-8.
46. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev 2005;15:97-101.
47. Furukawa T, Fu X, Kubota T, Watanabe M, Kitajima M, Hoffman RM. Nude mouse metastatic models of human stomach cancer constructed using orthotopic implantation of histologically intact tissue. Cancer Res 1993;53:1204-8.
48. Sun FX, Sasson AR, Jiang P, et al. An ultra-metastatic model of human colon cancer in nude mice. Clin Exp Metastasis 1999;17:41-8.
49. Hoffman RM. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. Methods Mol Med 2005;111:297-322.